Veran Medical Technologies is on the verge of closing yet another fundraising round in support of its electromagnetic airway mapping system, with just about $1 million to go.
Oncology
InSightec seeks $50M for ultrasound tumor therapy
Israel-based InSightec is looking for a few investors to jump in on its $50 million Series D funding round, saying it’ll use the funds to boost commercial efforts for its non-invasive tumor-targeting ultrasound therapy.
York Capital Management is already lined up to take a chunk out of the $50 million, leaving "limited time" for other prospective funders to jump in on the initial round or to expand fundraising to $62.5 million, InSightec said.
Press Release: EDAP completes FDA inspection of manufacturing site
LYON, France — EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that the U.S. Food and Drug Administration (FDA) concluded its routine inspection of EDAP’s manufacturing site with no findings nor issuance of Form 483 observations.
EDAP creeps toward FDA approval with clean inspection
Press Release: FDA approves Lymphoseek to help determine the extent of head and neck cancer in the body
The U.S. Food and Drug Administration today approved a new use for Lymphoseek (technetium 99m tilmanocept) Injection, a radioactive diagnostic imaging agent used to help doctors determine the extent a type of cancer called squamous cell carcinoma has spread in the body’s head and neck region.
FDA expands approval for Navidea’s Lymphoseek for head and neck cancers
Navidea Biopharmaceuticals landed FDA approval to expand use for its Lymphoseek imaging agent to help track cancers spreading in the head and neck.
Lymphoseek is the "1st and only FDA-approved radiopharmaceutical application for sentinel lymph node detection," according to Navidea, which originally won FDA approval for Lymphoseek in March 2013.
DFine launches tumor ‘melting’ trial
Spinal therapies maker DFine Inc. launched enrollment in a clinical trial of its STAR tumor ablation system, evaluating the technology in treatment of spinal tumors.
The new EU-STAR clinical trial will enroll 40 patients at 5 centers in Germany and France, DFine reported. Researchers are looking to examine patients’ pain from 1 month following the procedure out to 6 months, as well as patients’ function, quality of life and reliance on pain medications.
Intuitive Surgical sponsors women’s cancer registry
Verisante, Astoria join forces for upper GI cancer detection
J&J shelves surgical morcellators following FDA cancer warning
FDA warns that breaking up uterine tissue for removal may spread cancer
FDA officials issued a formal warning today asking doctors to avoid a certain method for removing uterine tissue out of concern that it may cause stealthy cancers to spread beyond the uterus.